Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-08

Clinical Trial Update: Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients [Phase 3]

View source ↗

Summary

Long-term Phase 3 safety study of tanezumab in osteoarthritis was terminated, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tanezumab (tanezumab)

Snippet

Sponsor: Pfizer | Conditions: Osteoarthritis | Phase 3 | Status: TERMINATED | Results posted: 2021-02-08